Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A2-ESO-1 TCR-T Cells in Relapsed/Refractory Advanced or Metastatic NY-ESO-1-Expressing TNBC
NCT05989828Phase 1Recruiting
- Sponsor
- University of Southern California
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in triple-negative breast cancer (TNBC), sponsored by University of Southern California. Primary endpoints: Maximum Tolerated Dose at 6 weeks and Incidence of Dose-Limiting Toxicities at 6 weeks. Started Dec 2024; status: recruiting.
02
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05989828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05989828.